Home
About
Board of Directors
Management
Scientific Advisory Board
Consultant Team
Technology
Tocotrienols
Nutraceuticals
Clinical Development Strategy
Why NAFLD/NASH
Why Pancreatic Cancer
The AZT Therapeutics Program
Investors
Corporate Governance
Corporate Directory
Announcements
Events
Contact
Announcements
Close of IPO and Name Change to VGI Health Technology Limited - 20 April 2021
Extension of Closing Date for IPO - 01 April 2021
Azure Health Technology Limited completes first manufacturing run in the US for nutraceutical products - 16 Mar 2021
AZT Announcement Replacement Prospectus and Opening of IPO - 5 Mar 2021
AZT Announcement Board Changes - 25 Feb 2021
AZT Press Release Malaysian Patent Granted - 25 Feb 2021
AZT IPO Proposed Capital Raise - 19 Feb 2021
ACCESS China Forum - An Introduction to Azure Health Technology Limited (AZT) - 21 Jan 2021
Brazilian Patent Application approved for granting - 19 Jan 2021
Azure Health Technology Limited's nutraceutical products listed on Australia's Therapeutic Goods Administration's (TGA"s) Australian Register of Therapeutic Goods (ARTG) as Listed Complementary Medicines - 18 Jan 2021
Capital Raising Update - 08 Dec 2020
Azure Health Technology Limited lodges new Australian Provisional Patent Application on Transmucosal Delivery of Tocotrienols - 07 Dec 2020
Listing Update
How to Vote Announcement
2020 AGM NOM and Proxy
2020 AGM Shareholder Q&A
Annual Report for the year ended 30 June 2020
Chinese Patent Application Granted for Transmucosal Delivery of tocotrienols - 01 October 2020
Board and Management Changes - 28 September 2020
Canadian Patent Office issues Notice of Allowance for Canadian Patent Application -
24 September 2020
Azure Health Technology completes study protocol for Pancreatic Cancer Phase II clinical study - 21 September 2020
Azure Health Technology Limited commences first manufacturing run in the US for nutraceutical products - 24 August 2020
Azure Health Technology Completes study protocol for NAFLD/NASH Phase II
clinical
study - 31 July 2020
Azure Health Technology Limited appoints Non-Executive Director - 02 July 2020
Azure Health Technology Limited commences preparations for pancreatic cancer Phase II clinical study - 22 June 2020
Azure Health Technology Limited commences preparations for NAFLD/NASH Phase II clinical study - 15 June 2020
Azure Health Technology Limited acquires Invictus BioPharma Limited - 11 June 2020
Azure Health Technology Limited successfully completes Capital Raise - 03 June 2020
TOP
